產(chǎn)品名稱 NN 414 - Tifenazoxide
產(chǎn)品貨號(hào) Axon 1647 CAS [279215-43-9] MF C9H10ClN3O2S2MW 291.78 Purity: 99% Soluble in DMSO Description A potent and Kir6.2/SUR1 selective K(ATP) channels opener, which inhibits glucose stimulated insulin release in vitro and in vivo and has beneficial effects on glucose homeostasis in preclinical and clinical studies. Unfortunately, its clinical development was recently suspended due to elevated liver enzymes References Certificates Categories Extra info RD Carr et al. NN414, a SUR1/Kir6.2-Selective Potassium Channel Opener, Reduces Blood Glucose and Improves Glucose Tolerance in the VDF Zucker Rat.?Diabetes 2003, 52(10), 2513-2518. ? M Zdravkovic et al. The effects of NN414, a SUR1/Kir6.2 selective potassium channel opener, in healthy male subjects.?J. Clin. Pharmacol. 2005, 45(7), 763-772. ? JB Hansen. Towards selective Kir6.2/SUR1 potassium channel openers, medicinal chemistry and therapeutic perspectives. Curr. Med. Chem. 2006, 13(4), 361-76. ? M Zdravkovic et al. The effects of NN414, a SUR1/Kir6.2 selective potassium channel opener in subjects with type 2 diabetes. Exp. Clin. Endocrinol Diabetes. 2007, 115(6), 405-406. Certificate of Analysis Material Safety Data Sheet Cardiovascular Cell Signaling & Oncology CNS Diabetes & Metabolism Endocrinology KCNJ11 Kir6.2-SUR1 K+ channel opener (SUR1/Kir6.2 selective) Chemical name 6-Chloro-3-(1-methylcyclopropylamino)-4H-thieno[3,2-e][1,2,4]thiadiazine-1,1-dioxide Parent CAS No. [279215-43-9] Order Size Unit Price Stock 5 mg €90.00 In Stock
產(chǎn)品價(jià)格 現(xiàn)貨詢價(jià),電話:010-67529703
產(chǎn)品規(guī)格
產(chǎn)品品牌 axonmedchem
產(chǎn)品概述
產(chǎn)品詳情

NN 414 - Tifenazoxide

Based on 8 reference(s) in Google Scholar 9 10 8

Axon 1647

CAS [279215-43-9]

MF C9H10ClN3O2S2
MW 291.78

  • Purity: 99%
  • Soluble in DMSO

NN 414

Description

A potent and Kir6.2/SUR1 selective K(ATP) channels opener, which inhibits glucose stimulated insulin release in vitro and in vivo and has beneficial effects on glucose homeostasis in preclinical and clinical studies. Unfortunately, its clinical development was recently suspended due to elevated liver enzymes
產(chǎn)品資料